Cambridge Innovation Capital is a Cambridge-based venture capital firm that specializes in early-stage and growth investments in life sciences and technology. It focuses on companies affiliated with the University of Cambridge or the Cambridge Cluster and seeks to back innovations in therapeutics, medtech and diagnostics, digital health, genomics and proteomics, artificial intelligence, the Internet of Things, quantum technologies, and autonomous systems. The organization provides long-term equity capital to help portfolio companies bridge development stages and scale, with a strong emphasis on opportunities arising from the Cambridge ecosystem. Since its founding in 2013, Cambridge Innovation Capital has established itself as a leading investor within that community, leveraging close ties to academia to access high-potential deep-tech opportunities.
Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.
Epitopea
Seed Round in 2022
Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.